CN102123722A - 改进的胆固醇流出的肽介质 - Google Patents

改进的胆固醇流出的肽介质 Download PDF

Info

Publication number
CN102123722A
CN102123722A CN2009801324185A CN200980132418A CN102123722A CN 102123722 A CN102123722 A CN 102123722A CN 2009801324185 A CN2009801324185 A CN 2009801324185A CN 200980132418 A CN200980132418 A CN 200980132418A CN 102123722 A CN102123722 A CN 102123722A
Authority
CN
China
Prior art keywords
polypeptide
seq
peptide
isolating
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801324185A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·K·别利茨基
简·约翰松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN102123722A publication Critical patent/CN102123722A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801324185A 2008-06-18 2009-06-17 改进的胆固醇流出的肽介质 Pending CN102123722A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7370808P 2008-06-18 2008-06-18
US61/073,708 2008-06-18
PCT/US2009/047694 WO2009155366A2 (en) 2008-06-18 2009-06-17 Improved peptide mediators of cholesterol efflux

Publications (1)

Publication Number Publication Date
CN102123722A true CN102123722A (zh) 2011-07-13

Family

ID=41434685

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801324185A Pending CN102123722A (zh) 2008-06-18 2009-06-17 改进的胆固醇流出的肽介质

Country Status (14)

Country Link
US (1) US8415293B2 (enExample)
EP (1) EP2300038A4 (enExample)
JP (1) JP2011525181A (enExample)
KR (1) KR20110043597A (enExample)
CN (1) CN102123722A (enExample)
AU (1) AU2009260024A1 (enExample)
BR (1) BRPI0915422A2 (enExample)
CA (1) CA2727465A1 (enExample)
CL (1) CL2010001445A1 (enExample)
IL (1) IL209868A0 (enExample)
MX (1) MX2010014003A (enExample)
PE (1) PE20110106A1 (enExample)
RU (1) RU2011101536A (enExample)
WO (1) WO2009155366A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105050614A (zh) * 2013-03-15 2015-11-11 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
CN110294791A (zh) * 2019-06-13 2019-10-01 倪京满 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139819A2 (en) * 2010-04-28 2011-11-10 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
MX2016014306A (es) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Marcadores para terapia con lipoproteinas de alta densidad (hdl).
US11091529B2 (en) 2014-09-17 2021-08-17 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
DK3319980T3 (da) * 2015-07-10 2021-11-22 Peptinovo Biopharma Inc Formuleringer til forbedring af virkningen af hydrofobe lægemidler
EP3464613A4 (en) 2016-05-31 2020-01-08 Institut de Cardiologie de Montréal CO-CULTURE SYSTEM AND METHOD FOR IN-VITRO EVALUATION OF CHOLESTERIN RETURN
CN111848742B (zh) * 2020-07-23 2021-03-23 南京医科大学 一种多肽及其制药用途
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691965B2 (en) * 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
CA2672131C (en) 2006-12-13 2016-06-07 The Regents Of The University Of California Potent and selective mediators of cholesterol efflux

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105050614A (zh) * 2013-03-15 2015-11-11 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
CN105050614B (zh) * 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
CN110294791A (zh) * 2019-06-13 2019-10-01 倪京满 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
CN110294791B (zh) * 2019-06-13 2023-02-21 倪京满 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Also Published As

Publication number Publication date
CL2010001445A1 (es) 2012-03-16
CA2727465A1 (en) 2009-12-23
AU2009260024A1 (en) 2009-12-23
WO2009155366A3 (en) 2010-04-22
BRPI0915422A2 (pt) 2017-06-27
JP2011525181A (ja) 2011-09-15
US8415293B2 (en) 2013-04-09
RU2011101536A (ru) 2012-07-27
PE20110106A1 (es) 2011-03-02
IL209868A0 (en) 2011-02-28
KR20110043597A (ko) 2011-04-27
MX2010014003A (es) 2011-02-15
EP2300038A2 (en) 2011-03-30
EP2300038A4 (en) 2013-09-04
US20110190196A1 (en) 2011-08-04
WO2009155366A2 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
US8415293B2 (en) Peptide mediators of cholesterol efflux
AU2004299486B2 (en) Helical synthetic peptides that stimulate cellular cholesterol efflux
US11434267B2 (en) Peptides having reduced toxicity that stimulate cholesterol efflux
EP2121746B1 (en) Potent and selective mediators of cholesterol efflux
US20130123173A1 (en) Creation of oxidation-resistant hdl mimetic peptides
HK1138292B (en) Potent and selective mediators of cholesterol efflux
US20100204103A1 (en) Helical synthetic peptides that stimulate cellular cholesterol efflux

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110713